Background: Thymol is a transient receptor potential ankyrin subtype 1 channel,
| Reagents
Thymol was purchased from Sigma and 2M stock solutions made up in 100% DMSO for all cell-based assays and all animal studies. Variations in the final DMSO concentrations between experiments are due to utilization of different working stocks; however, all final DMSO concentrations were maintained at or below 0.5% so as not to affect the results. In addition, vehicle controls contained the same concentration of DMSO as treated groups.
| MTS cell viability assays
Cytotoxicity was assessed using the Cell Titer 96
â Aqueous NonRadioactive Cell Proliferation Assay (Promega, Madison, WI, USA)
according to manufacturer's protocol. Cells were plated and treated for 48 hours with DMEM containing thymol at the indicated concentrations as previously described. 22 Final DMSO concentrations were maintained at 0.1%. Absorbance values of test groups were compared to vehicle-treated controls (n = 4).
| In vitro clonogenic assays
Cells (300 cells per plate) were allowed to adhere in 60 mm 3 tissue culture dishes and subsequently treated with vehicle (final concentration of 0.5% DMSO) or thymol (4.3 mmol/L) for 2 minutes. Cells were washed with sterile phosphate-buffered saline (PBS), fresh growth medium was added, and cells were allowed to grow and form colonies for 9 days. Following the incubation period, cells were fixed and stained with 0.5% crystal violet in 10% methanol, washed with PBS, and quantified using GeneTools software.
| Antitumor evaluations
All studies were approved by our Institutional Animal Care and Use
Committee and conform to ARRIVE guidelines. Six-week-old female 
| Mitochondrial membrane potential
Cells were plated at 5 9 10 5 in 60 mm dishes, grown overnight, and treated for 2 hours with thymol diluted at the indicated concentrations. Cells were then stained with 1 lmol/L JC-1 dye (Thermo Fisher Scientific, Waltham, MA, USA) for 15 minutes at 37°C, washed, and analyzed by FACS analysis. 
| Western blot analysis

| Statistical analysis
Statistical analyses were performed using GraphPad Prism 4 (San Diego, CA, USA). Cell viability and mitochondrial membrane potential results were analyzed by 1-way ANOVA and Bonferroni's post hoc test (n = 4 and n = 3 per group, respectively). Statistical analyses of tumor growth and body weight were made using 2-way analysis of variance with repeated measures with Bonferroni's post hoc test.
Data are presented as mean AE SD. Ki67 staining and TUNEL assays were analyzed by a Student's t test; data are presented as mean AE SEM. A P value less than .05 was considered statistically significant.
| RESULTS
| Thymol has antiproliferative effects in multiple cancer cell types
Given that thymol is found in numerous commercial products including Listerine, we questioned whether thymol is cytotoxic to oral cancer cells. Thus, we initially performed cell viability assays using OSCC cell lines Cal27, SCC4, and SCC9. Thymol induced a concentration-dependent reduction in cell viability in all OSCC cell lines tested at concentrations that are dramatically lower than the con- (Figure 1B) . Similarly, thymol induced a concentration-dependent reduction in cell viability in all cancer cell lines tested with GC 50s ranging from 350 lmol/L to 500 lmol/L indicating that thymol's cytotoxic effects are not specific to oral cancers.
| Thymol has long-lasting cytotoxic effects
Clonogenic assays were performed to determine whether a shortterm exposure to thymol at the concentration found in commercial products such as Listerine (4.3 mmol/L) has long-lasting antiproliferative effects. Cal27 and HeLa cells treated for 2 minutes with thymol 
| Thymol significantly inhibits tumor growth in vivo
To determine whether thymol has antitumor effects against OSCC, we generated Cal27-derived xenografts in athymic nude mice. Figure 3B ).
F I G U R E 5 TRPA1 inhibition reduces calcium influx in Cal27 cells, whereas the TRPM8 inhibitor does not. A, Calcium imaging of Cal27 cells pre-treated with the TRPA1 antagonist, HC030031 (10 lmol/L), followed by thymol (400 lmol/L) compared to thymol alone (400 lmol/L) shows a dramatic reduction in calcium influx. B, Calcium imaging of Cal27 cells pre-treated with the TRPM8 antagonist, RQ00203078 (10 lmol/L), followed by thymol (400 lmol/L) compared to thymol alone (400 lmol/L) has a muted calcium influx even in the presence of TRPM8 inhibition. C, MTS cell viability assay of Cal27 cells treated with thymol (350 lmol/L), HC030031 (10 lmol/L; TRPA1 antagonist), RQ00203078 (10 nM; TRPM8 antagonist), or pre-treated with the TRPA1 or TRPM8 inhibitors followed by thymol (350 lmol/L). **P < 0.01
| Thymol OSCC cytotoxicity is through a unique mechanism that does not involve TRP channel activation
Thymol is a known TRPA1 agonist and is also reported to activate TRPV3 and weakly TRPM8 channels. To determine whether thymol cytotoxicity is mediated by TRP channel activation in OSCC, we performed calcium imaging studies using Cal27 and HeLa cells in addition to CHO cells that overexpress TRPA1 (CHO-TRPA1; positive control) and TRPV1 (CHO-TRPV1; negative control). While lower thymol concentrations (<400 lmol/L) failed to activate CHO-TRPA1 channels (data not shown), 400 lmol/L thymol successfully induced calcium influx in CHO-TRPA1 cells with no effect on calcium influx in CHO-TRPV1 cells ( Figure 4A ,B, respectively). Likewise, 400 lmol/ L thymol induced calcium influx in Cal27 cells with no effect on HeLa cells which do not express TRPA1 channels (data not shown; Figure 4C ,D, respectively). Treatment with the non-selective cation channel agonist Ionomycin (3 lmol/L) confirmed calcium influx of both cell lines in response to cation channel activation, with HeLa cells being much less responsive. We confirmed that the calcium influx in Cal27 cells is due primarily to TRPA1 activation, which was reversed when the cells were pre-treated with the TRPA1 inhibitor, HC030031 ( Figure 5A ). Pre-treatment with the TRPM8 inhibitor, RQ00203078, muted the response to thymol but did not abolish it ( Figure 5B ). There are no commercially available TRPV3 inhibitors; thus, we did not assess TRPV3 activity in Cal27 cells. Taken together, these data suggest that the calcium influx in Cal27 cells is primarily due to TRPA1 activation. Notably, the antiproliferative mechanism-of-action most likely does not involve TRP channel activity given the significant antiproliferative effects seen in HeLa cells, which do not exhibit thymol-induced calcium influx. Furthermore, while TRP channel activation occurs at concentrations similar to the GC 50 (350 lmol/L), cell viability assays reveal that TRPA1 inhibition and TRPM8 inhibition do not reverse thymol's cytotoxicity in vitro ( Figure 5C ), confirming that TRP channel activation is not the mechanism-of-action for thymol's antitumor effects. 
| DISCUSSION
Thymol is a known agonist for TRPA1, TRPV3, and weakly activates TRPM8 and thus is deemed a potential therapy for cancers that overexpress these channels. We demonstrate, for the first time, the therapeutic potential of thymol against OSCC and confirm anticancer effects in the absence of TRP channel activation. Studies evaluating thymol-induced calcium influx in MG63 osteosarcoma cells and DBTRG-05MG glioblastoma cells confirmed a dose-dependent calcium influx that correlated with cytotoxic concentrations. 8, 19 While these studies did not evaluate TRP channels specifically, the primary source of calcium was found to be from Thymol is a phenolic compound that reportedly has antioxidant activity at low concentrations and pro-oxidant activities at high concentrations. 24 Our studies found similar GC 50 values in Cal27 and into the cytosol, which interferes with the accuracy of DΨ m dyes that serve as indirect measures of the mitochondrial pH values. 25 Nevertheless, as thymol concentrations increased, mitochondrial membrane potential decreased and apoptosis ensued.
The hydrophobic nature of thymol allows it to interact with lipids found in the cell and in mitochondrial membranes. In addition, thymol is a redox inhibitor that interferes with electron transport similar to vanilloids thereby inducing apoptosis. 26 Accordingly, studies of thymol in B16 melanoma cells show that thymol cytotoxicity is reversible with the addition of vitamin C or vitamin E. 27 Likewise, we show that thymol cytotoxicity in OSCC is reversed by the addition of the antioxidant NAC providing further evidence that the anticancer mechanism-of-action of thymol involves mitochondrial dysfunction, generation of free radicals, and subsequent apoptosis.
Importantly, we show for the first time that thymol has significant antitumor effects in Cal27 and HeLa xenografts with no adverse effects on adjacent non-malignant tissues at concentrations that are FDA-approved for commercial products. Thus, thymol may also have chemopreventive effects against oral cancers and, more importantly, can be further developed to treat OSCC. 
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